Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: studies in 5/6 nephrectomized rats with aorto-caval fistula
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083626" target="_blank" >RIV/00023001:_____/23:00083626 - isvavai.cz</a>
Alternative codes found
RIV/67985823:_____/23:00568956 RIV/00216208:11130/23:10452798 RIV/61989592:15110/23:73619154 RIV/00098892:_____/23:10158364 RIV/00064203:_____/23:10452798
Result on the web
<a href="https://reader.elsevier.com/reader/sd/pii/S0753332222015463?token=5CCD3BF1D968FED00BE1B886260DEC141309A29A5DFA3A23EBCFB4309E9548E79A30532D0BFAFAFD99D0BEF026B531F8&originRegion=eu-west-1&originCreation=20230221103007" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0753332222015463?token=5CCD3BF1D968FED00BE1B886260DEC141309A29A5DFA3A23EBCFB4309E9548E79A30532D0BFAFAFD99D0BEF026B531F8&originRegion=eu-west-1&originCreation=20230221103007</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.biopha.2022.114157" target="_blank" >10.1016/j.biopha.2022.114157</a>
Alternative languages
Result language
angličtina
Original language name
Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: studies in 5/6 nephrectomized rats with aorto-caval fistula
Original language description
Background: Association of congestive heart failure (CHF) and chronic kidney disease (CKD) worsens the patient's prognosis and results in poor survival rate. The aim of this study was to examine if addition of endothelin type A (ETA) receptor antagonist to the angiotensin-converting enzyme inhibitor (ACEi) will bring additional beneficial effects in experimental rats.Methods: CKD was induced by 5/6 renal mass reduction (5/6 NX) and CHF was elicited by volume overload achieved by creation of aorto-caval fistula (ACF). The follow-up was 24 weeks after the first intervention (5/6 NX). The treatment regimens were initiated 6 weeks after 5/6 NX and 2 weeks after ACF creation.Results: The final survival in untreated group was 15%. The treatment with ETA receptor antagonist alone or ACEi alone and the combined treatment improved the survival rate to 64%, 71% and 75%, respectively, however, the difference between the combination and either single treatment regimen was not significant. The combined treatment exerted best renoprotection, causing additional reduction in albuminuria and reducing renal glomerular and tubulointerstitial injury as compared with ACE inhibition alone.Conclusions: Our results show that treatment with ETA receptor antagonist attenuates the CKD-and CHF-related mortality, and addition of ETA receptor antagonist to the standard blockade of RAS by ACEi exhibits additional renoprotective actions.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedicine and pharmacotherapy
ISSN
0753-3322
e-ISSN
1950-6007
Volume of the periodical
158
Issue of the periodical within the volume
February
Country of publishing house
FR - FRANCE
Number of pages
11
Pages from-to
"art. no. 114157"
UT code for WoS article
000916209900001
EID of the result in the Scopus database
2-s2.0-85145296028